Novus Therapeutics (NASDAQ:NVUS) Releases Quarterly Earnings Results, Beats Expectations By $0.18 EPS

Share on StockTwits

Novus Therapeutics (NASDAQ:NVUS) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.18, Fidelity Earnings reports.

Shares of NASDAQ:NVUS traded up $0.01 during midday trading on Thursday, reaching $0.63. The company had a trading volume of 30,100 shares, compared to its average volume of 98,630. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.79 and a quick ratio of 7.79. The stock’s fifty day moving average price is $0.60 and its 200-day moving average price is $1.09. The stock has a market capitalization of $9.34 million, a P/E ratio of -0.41 and a beta of 2.86. Novus Therapeutics has a one year low of $0.40 and a one year high of $5.21.

NVUS has been the topic of several research analyst reports. ValuEngine cut shares of Novus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, September 4th. Zacks Investment Research cut shares of Novus Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 22nd. Finally, LADENBURG THALM/SH SH reissued a “buy” rating and set a $10.00 target price on shares of Novus Therapeutics in a research report on Monday, August 19th.

About Novus Therapeutics

Novus Therapeutics, Inc, a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection).

Recommended Story: What is a CD ladder?

Earnings History for Novus Therapeutics (NASDAQ:NVUS)

Receive News & Ratings for Novus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Gran Colombia Gold  Stock Price Crosses Above Two Hundred Day Moving Average of $4.78
Gran Colombia Gold Stock Price Crosses Above Two Hundred Day Moving Average of $4.78
AGF Management  Shares Cross Above 200 Day Moving Average of $5.56
AGF Management Shares Cross Above 200 Day Moving Average of $5.56
Endeavour Silver  Share Price Crosses Below 200-Day Moving Average of $2.99
Endeavour Silver Share Price Crosses Below 200-Day Moving Average of $2.99
Victrex  Downgraded by Zacks Investment Research to “Sell”
Victrex Downgraded by Zacks Investment Research to “Sell”
Regal Beloit Corp  Expected to Post Earnings of $1.25 Per Share
Regal Beloit Corp Expected to Post Earnings of $1.25 Per Share
$1.50 EPS Expected for ViacomCBS Inc.  This Quarter
$1.50 EPS Expected for ViacomCBS Inc. This Quarter


© 2006-2019 Ticker Report